Dr. Jared Weiss, MD
Claim this profileLineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill
Area of expertise
Lung Cancer
Jared Weiss, MD has run 9 trials for Lung Cancer. Some of their research focus areas include:
Head And Neck Cancers
Jared Weiss, MD has run 7 trials for Head and Neck Cancers. Some of their research focus areas include:
Affiliated Hospitals
Lineberger Comprehensive Cancer Center At University Of North Carolina - Chapel Hill
University Of North Carolina At Chapel Hill
Clinical Trials Jared Weiss, MD is currently running
CAR T-Cell Therapy
for Lung Cancer
This is a phase 1, single-center, open-label study that enrolls adult subjects with extensive stage lung cancer or stage IV non-small cell lung cancer that is platinum-refractory and received PD-1 and/or PD-L1 therapy. The purpose of this study is to test the safety of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the GD2 antigen (iC9-GD2.CAR.IL-15 T cells) in subjects with lung cancer. How much (dose) of the iC9-GD2.CAR.IL-15 T cells are safe to use without causing too many side effects and what is the maximum dose that could be tolerated will be studied. Modified immune cells as an experimental treatment that combines antibodies and T cells will be used. Antibodies are proteins that protect the body from foreign invaders like bacteria. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill viruses and other cells, including tumor cells. Although antibodies and T cells have been used to treat cancer and they both have shown promise, neither alone has been able to cure most patients. This study will combine T cells and antibodies to create a more effective treatment. The treatment that is being researched in this study is called autologous T lymphocyte chimeric antigen receptor cells targeted against the disialoganglioside (GD2) antigen that expresses Interleukin (IL)-15, and the inducible caspase 9 safety switch (iC9). The short name for this treatment is iC9.GD2.CAR.IL-15 T cells therapy is an experimental therapy and has not been approved by the Food and Drug Administration. There are two steps. In the first step, blood will be collected from the subjects to prepare the iC9-GD2.CAR.IL-15 T cells. T cells will be isolated from the blood and modified to make iC9-GD2.CAR.IL-15. In the second step, the iC9-GD2.CAR.IL-15 T cells produced from the subject's own blood will be administered to the subject.
Recruiting
1 award
Phase < 1
6 criteria
Trilaciclib + Lurbinectedin
for Small Cell Lung Cancer
Lung cancer is by far the leading cause of cancer death among both men and women worldwide and the second most common cancer in terms of new cases. Small cell lung cancer (SCLC) is the deadliest form of lung cancer. The standard first-line treatment is the combination of carboplatin, etoposide, and atezolizumab. While response rates for this regimen are high (roughly 60%), the duration of response is short, typically 4 months. Following progression after the 1st line treatment of SCLC, there is no consensus regarding subsequent therapy. Lurbinectedin is FDA approved and is increasingly preferred in clinical practice. Toxicity was significant, but appeared favorable compared to historic results with topotecan, leading to the adoption of this therapy for second-line SCLC. The toxicity profile was dominated by myelosuppression. This study investigates the effect of Trilaciclib on myelosuppression rate in subjects with platinum refractory extensive stage (ES)- SCLC receiving Lurbinectedin as well as the clinical synergy of Trilaciclib and Lurbinectedin combination.
Recruiting
1 award
Phase 2
5 criteria
More about Jared Weiss, MD
Clinical Trial Related
4 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Jared Weiss, MD has experience with
- Pembrolizumab
- Carboplatin
- Cisplatin
- Durvalumab
- PANDA-VAC
- IMRT
Breakdown of trials Jared Weiss, MD has run
Lung Cancer
Head and Neck Cancers
Cancer
Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jared Weiss, MD specialize in?
Jared Weiss, MD focuses on Lung Cancer and Head and Neck Cancers. In particular, much of their work with Lung Cancer has involved RET positive patients, or patients who are Stage IV.
Is Jared Weiss, MD currently recruiting for clinical trials?
Yes, Jared Weiss, MD is currently recruiting for 4 clinical trials in Chapel Hill North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Jared Weiss, MD has studied deeply?
Yes, Jared Weiss, MD has studied treatments such as Pembrolizumab, Carboplatin, Cisplatin.
What is the best way to schedule an appointment with Jared Weiss, MD?
Apply for one of the trials that Jared Weiss, MD is conducting.
What is the office address of Jared Weiss, MD?
The office of Jared Weiss, MD is located at: Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill, North Carolina 27599 United States. This is the address for their practice at the Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.